LON:GSK GSK (GSK) Share Forecast, Price & News GBX 1,527.80 -2.80 (-0.18%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range 1,518.60▼ 1,544.2050-Day Range 1,318.60▼ 1,534.4052-Week Range 1,286.20▼ 1,609Volume7.13 million shsAverage Volume7.08 million shsMarket Capitalization£62.64 billionP/E Ratio1,202.99Dividend Yield3.67%Price TargetGBX 1,572.50 ProfileProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlinesOptions ChainSustainabilityProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlinesOptions ChainSustainability GSK MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside2.9% UpsideGBX 1,572.50 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-1.56Upright™ Environmental ScoreNews Sentiment0.55Based on 7 Articles This WeekInsider TradingSelling Shares£67.32 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 stars 2.1 Analyst's Opinion Consensus RatingGSK has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 1,572.50, GSK has a forecasted upside of 2.9% from its current price of GBX 1,527.80.Amount of Analyst CoverageGSK has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GSK. Previous Next 1.7 Dividend Strength Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 3.63%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 4,409.45%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGSK has received a 66.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "HIV medication", "Shingles vaccines", "Mouthwash", "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Clinical research services for the respiratory system" products. See details.Environmental SustainabilityThe Environmental Impact score for GSK is -1.56. Previous Next 2.5 News and Social Media Coverage News SentimentGSK has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for GSK this week, compared to 5 articles on an average week.Search InterestOnly 47 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows7 people have added GSK to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GSK insiders have sold 7,755.51% more of their company's stock than they have bought. Specifically, they have bought £8,570.04 in company stock and sold £673,220.52 in company stock.Percentage Held by InsidersOnly 1.74% of the stock of GSK is held by insiders.Percentage Held by Institutions45.00% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 1,202.99, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 110.85.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 1,202.99, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 106.22.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.02. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioGSK has a P/B Ratio of 4.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About GSK (LON:GSK) StockGSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.Read More GSK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GSK Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comGSK plc (LON:GSK) Insider Hal Barron Acquires 219 Shares of StockSeptember 21, 2023 | finance.yahoo.comBiotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY DownSeptember 24, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 19, 2023 | benzinga.comHow Is The Market Feeling About GSK?September 19, 2023 | markets.businessinsider.comGSK : EC Authorizes ViiV Healthcare's Apretude For HIV PreventionSeptember 19, 2023 | americanbankingnews.comGSK (LON:GSK) Given New GBX 1,575 Price Target at BarclaysSeptember 16, 2023 | americanbankingnews.comGSK (LON:GSK) Stock Passes Above 200 Day Moving Average of $1,407.79September 15, 2023 | finance.yahoo.comUPDATE 1-US FDA approves GSK's blood cancer therapySeptember 24, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 15, 2023 | reuters.comUS FDA approves GSK's anemia treatmentSeptember 15, 2023 | investing.comGSK shares rise in sync with FTSE 100, nearing 52-week highSeptember 15, 2023 | msn.comGSK launches £65m drug factory in HertfordshireSeptember 14, 2023 | msn.comBoost for British life sciences as GSK launches £65m drug factory in HertfordshireSeptember 13, 2023 | msn.comIDEAYA's Triple Threat: Melanoma, Money, And MomentumSeptember 13, 2023 | msn.comModerna says mRNA flu shot generates better immune response in study than currently available vaccineSeptember 11, 2023 | reuters.comBRIEF-Gsk Says Momelotinib Filing Accepted In JapanSeptember 11, 2023 | msn.comGSK (GSK) Moves 5.5% Higher: Will This Strength Last?September 8, 2023 | finance.yahoo.comUnveiling GSK PLC (GSK)'s Value: Is It Really Priced Right? A Comprehensive GuideSeptember 7, 2023 | msn.comIonis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-ComersSeptember 5, 2023 | msn.comPepsi, General Mills, GSK, U. of Phoenix Execs To Talk Marketing at Advanced Advertising SummitSeptember 5, 2023 | businesswire.comGSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA LocationsSeptember 5, 2023 | finance.yahoo.comGSK and Earvin "Magic" Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA LocationsSeptember 1, 2023 | msn.comBRIEF-GSK Says Nucala CRSwNP Submission Accepted In JapanAugust 30, 2023 | benzinga.comGSK To Invest $272M In New Vaccine Facility Near Brussels, Slated To Open In 2027August 30, 2023 | msn.comGSK Invests €250 Million to Allow Freeze-Drying of VaccinesAugust 25, 2023 | finance.yahoo.comHere's Why GSK (GSK) is a Strong Value StockAugust 25, 2023 | finance.yahoo.comGlaxo (GSK) Down 3.9% Since Last Earnings Report: Can It Rebound?See More Headlines Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address GSK Company Calendar Last Earnings7/29/2020Ex-Dividend for 7/13 Dividend5/18/2023Dividend Payable7/13/2023Ex-Dividend for 10/12 Dividend8/17/2023Today9/24/2023Dividend Payable10/12/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Drug Manufacturers—General Sub-IndustryN/A SectorMedical Current SymbolLON:GSK CUSIPN/A CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees69,400Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 1,572.50 High Stock Price ForecastGBX 2,000 Low Stock Price ForecastGBX 1,245 Forecasted Upside/Downside+2.9%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 1.27 Trailing P/E Ratio1,202.99 Forward P/E Ratio9.80 P/E Growth1.02Net Income£5.37 billion Net Margins52.60% Pretax MarginN/A Return on Equity33.22% Return on Assets6.71% Debt Debt-to-Equity Ratio176.61 Current Ratio0.88 Quick Ratio0.73 Sales & Book Value Annual Sales£29.33 billion Price / Sales2.14 Cash FlowGBX 187.57 per share Price / Cash Flow8.15 Book ValueGBX 313 per share Price / Book4.88Miscellaneous Outstanding Shares4,100,000,000Free FloatN/AMarket Cap£62.64 billion OptionableOptionable Beta0.30 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMs. Emma Natasha Walmsley (Age 53)CEO & Director Comp: $4.79MMs. Julie Belita Brown (Age 61)CFO & Exec. Director Ms. Shobie RamakrishnanChief Digital & Technology OfficerMr. Tony WoodChief Scientific OfficerMs. Sarah Elton-FarrHead of Investor RelationsMr. James FordSr. VP & Group Gen. Counsel of Legal & ComplianceMs. Sally JacksonSr. VP of Global Communications & CEO OfficeMr. David Simon Redfern BSc (Hons) (Age 57)CA, Pres of Corp. Devel. Ms. Diana ConradChief People OfficerMr. Philip C. ThomsonPres of Global AffairsMore ExecutivesKey CompetitorsAstraZenecaLON:AZNHaleonLON:HLNDechra PharmaceuticalsLON:DPHSmith & NephewLON:SNHikma PharmaceuticalsLON:HIKView All CompetitorsInsidersHal BarronBought 219 shares on 9/20/2023Total: £832,857.00 ($3,803.00/share)Hal BarronSold 19,446 sharesTotal: £67.32 M ($3,462.00/share)Emma WalmsleyBought 9 shares on 8/9/2023Total: £12,384.00 ($1,376.00/share)Emma WalmsleyBought 9 shares on 7/11/2023Total: £11,763.00 ($1,307.00/share)Jonathan SymondsBought 6,000 shares on 6/23/2023Total: £8.64 M ($1,440.00/share)View All Insider Transactions GSK Stock - Frequently Asked Questions Should I buy or sell GSK stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares. View GSK analyst ratings or view top-rated stocks. What is GSK's stock price forecast for 2023? 8 brokers have issued 1 year price targets for GSK's shares. Their GSK share price forecasts range from GBX 1,245 to GBX 2,000. On average, they expect the company's share price to reach GBX 1,572.50 in the next twelve months. This suggests a possible upside of 2.9% from the stock's current price. View analysts price targets for GSK or view top-rated stocks among Wall Street analysts. How have GSK shares performed in 2023? GSK's stock was trading at GBX 1,437.60 at the beginning of 2023. Since then, GSK shares have increased by 6.3% and is now trading at GBX 1,527.80. View the best growth stocks for 2023 here. How were GSK's earnings last quarter? GSK plc (LON:GSK) released its earnings results on Wednesday, July, 29th. The company reported $56.90 earnings per share (EPS) for the quarter. GSK had a net margin of 52.60% and a trailing twelve-month return on equity of 33.22%. How often does GSK pay dividends? What is the dividend yield for GSK? GSK announced a dividend on Wednesday, July 26th. Investors of record on Thursday, August 17th will be paid a dividend of GBX 14 per share on Thursday, October 12th. This represents a dividend yield of 1.01%. The ex-dividend date is Thursday, August 17th. The official announcement can be seen at this link. Read our dividend analysis for GSK. Is GSK a good dividend stock? GSK (LON:GSK) pays an annual dividend of GBX 56 per share and currently has a dividend yield of 3.63%. The dividend payout ratio is 4,409.45%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for GSK. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD). What is GSK's stock symbol? GSK trades on the London Stock Exchange (LON) under the ticker symbol "GSK." How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is GSK's stock price today? One share of GSK stock can currently be purchased for approximately GBX 1,527.80. How much money does GSK make? GSK (LON:GSK) has a market capitalization of £62.64 billion and generates £29.33 billion in revenue each year. The company earns £5.37 billion in net income (profit) each year or GBX 1.27 on an earnings per share basis. How many employees does GSK have? The company employs 69,400 workers across the globe. How can I contact GSK? GSK's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The official website for the company is www.gsk.com. The company can be reached via phone at +44-20-80475000. This page (LON:GSK) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.